FDA Approves Ojjaara as First-Line Treatment for Myelofibrosis Patients with Anemia

The US FDA has approved Ojjaara (momelotinib), developed by GSK, as the first and only treatment for myelofibrosis patients with anaemia, regardless of prior myelofibrosis therapy. Myelofibrosis is a rare blood cancer that often leads to anaemia, fatigue, and an enlarged spleen. Ojjaara addresses these key manifestations of the disease and offers a new treatment option for patients who have limited options to manage their condition.